Discovery & origin

• What Semax is and how an ACTH fragment became a brain peptide
• How it changes BDNF and NGF expression without raising cortisol
• How to weigh Russian clinical trials against Western RCT standards
• Where the evidence is solid, thin, or simply missing

1. 01 Discovery & origin From an ACTH fragment to a Russian brain peptide free
2. 02 Neuropeptide pharmacology Where Semax sits in the melanocortin family paid
3. 03 Chemistry & pharmacokinetics The structure, the breakdown, and the puzzle in between paid
4. 04 Neurotrophic mechanisms The BDNF and NGF signature paid
5. 05 Neurochemistry How Semax tunes brain messengers paid
6. 06 Cognitive effects The nootropic claim, examined paid
7. 07 Neuroprotection & stroke The strongest clinical signal, and its limits paid
8. 08 Safety & side effects What we know, and the large gaps we do not paid
9. 09 Dosing & administration How Semax is prepared and given, for education only paid
10. 10 Regulatory landscape Approved in Russia, unapproved in the West paid
11. 11 Final exam & certification Pass the final exam to earn your certificate of completion. Exam

Semax grew out of a longer tradition of research on ACTH- and MSH-derived neuropeptides. The foundational review of that family, by de Wied and Jolles in 1982, is where the idea of brain-active hormone fragments was consolidated. It is cited here as the tradition Semax descends from rather than quoted for any specific finding.

Russian researchers turned that idea into a drug, keeping the ACTH(4-7) core and adding a Pro-Gly-Pro tail. Their 1997 retrospective, titled as fifteen years of experience in its design and study, calls Semax one of the rare regulatory-peptide analogues that went from fundamental study to practical use. Russian regulators authorized it for medical use on 20 December 1994. More than thirty years later, FDA reviewers found that it is not a component of any FDA-approved drug and that the evidence of effectiveness for the uses they weighed was insufficient.

Strip away the marketing and Semax is seven amino acids in a row. The first four, Met-Glu-His-Phe, are the active ACTH core; the last three, Pro-Gly-Pro, are a stabilising tail added to slow the enzymes that take the peptide apart.

That small change in design is the whole point. FDA reviewers write that the C-terminal Pro-Gly-Pro is thought to increase the peptide’s stability against enzymes, and a 2025 paper credits it with increased resistance to peptidases. Even with the tail, the intact peptide is degraded rapidly, and the Pro-Gly-Pro fragment is what dominates biological samples soon after a dose. None of the sources this course cites gives a stability figure for the bare core without the tail, so treat the tail as a described stabiliser rather than a measured rescue. The tail itself, once cleaved off, is not inert: on its own it improved neuron survival in culture.

It helps to see Semax as a deliberate edit of a natural sequence. The body cuts a large precursor, pro-opiomelanocortin, into ACTH and related peptides; the precursor’s reference record gives ACTH as a chain of thirty-nine residues whose first ten run Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly. Semax keeps positions 4 to 7 of that hormone, Met-Glu-His-Phe, and adds a Pro-Gly-Pro tail. FDA reviewers summarize the idea behind such fragments: the ACTH(4-10) fragment is devoid of ACTH’s hormonal corticotropic properties but keeps its neurobehavioral ones, and the tail is thought to make the chain more stable against enzymes.

Before any mechanisms, here is the honest picture. The Semax evidence base is unusual: a deep body of animal mechanism work, a layer of Russian clinical trials cited in detail for only one study (2018) and otherwise through their abstracts, and a 2026 FDA review that found too little evidence of effectiveness for the three uses it weighed. That shape matters, because it is easy to mistake a tall stack of animal studies for clinical proof. The mechanism evidence is genuinely strong, the human evidence is genuinely thin, and much of both shares authors: one name, N. F. Myasoedov (also spelled Miasoedov), sits on the 1997 design retrospective, the 1997 stroke trial, the 2006 brain-uptake study and the 2007 neurotrophin study this course leans on. One housekeeping note before the tiers: the tier labels and the 0-to-10 gauges in this course are this course’s reading of the evidence, not scores any study measured.

Online, Semax is sold as a sharpening, focus-boosting nootropic. Held against the evidence, most of those claims are not flatly false, they are simply running far ahead of what has actually been tested in people.

Notice the pattern across the table. The mechanism claims are the best supported, the clinical claims are suggestive but soft, and the healthy-user claims that drive demand are the weakest. Reading each claim against its own evidence tier is the core skill this course builds.